Skip to main content
SpringerLink
Log in

Percutaneous radiotherapy for low-risk prostate cancer: options for 2007

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Technical developments of radiotherapy (RT) over the recent years yielded in better conformation to the target volume thus increasing the therapeutic ratio and decreasing side effects. This paper discusses these options for low-risk prostate cancer. There has been evidence from randomized trials, that for low-risk PCA doses >70 Gy are significant better in case of biochemical disease-free survival (bNED). Image-guided radiotherapy (IGRT) has been proven in several studies for reduced safety margins around the prostate target volume. Intensity-modulated radiotherapy (IMRT) allow treatment with higher doses and 5-year results are reported from several studies. Data from several randomized trials about adjuvant RT after radical prostatectomy (RP) have been reported. In two phase-III trials a significant advantage of 20% bNED was demonstrated for doses between 76 and 79 Gy compared with 70 Gy. Using IGRT, the safety margin around the prostate can be reduced for about 30–50%. Doses of >80 Gy can be given safely to the prostate with IMRT and <5% grade-III/IV late side effects. Adjuvant RT for positive margins after RP has been of proven advantage. Three phase-III trials achieved a significant better bNED of 20% for 5 years. The effect of doses >70 Gy have been proven for low-risk PCA. IGRT resulted in reduced safety margins and a decrease of acute and late side effects. The addition of IMRT allowed higher doses to the prostate. Adjuvant RT after RP for positive margins achieved a significant better bNED.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schostak M, Wiegel T, Muller M, Hoecht S, Schrader M, Straub B, Bottke D, Hinkelbein W, Miller K (2004) Shared decision-making—results from an interdisciplinary consulting service for prostate cancer. World J Urol 22:441–448

    Article  PubMed  CAS  Google Scholar 

  2. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG–ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974

    Article  PubMed  Google Scholar 

  3. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I (2002) Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105

    Article  PubMed  Google Scholar 

  4. Zapatero A, Valcárcel F, Calvo FA, Algás R, Béjar A, Maldonado J, Villá S (2005) Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol 23:6561–6568

    Article  PubMed  Google Scholar 

  5. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285–1290

    Article  PubMed  CAS  Google Scholar 

  6. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25–33

    Article  PubMed  Google Scholar 

  7. Speight JL, Roach M 3rd (2005) Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol 32:8176–8185

    Article  Google Scholar 

  8. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176:1415–1419

    Article  PubMed  Google Scholar 

  9. Scarbrough TJ, Golden NM, Ting JY, Fuller CD, Wong A, Kupelian PA, Thomas CR Jr (2006) Comparison of ultrasound and implanted seed marker prostate localization methods: implications for image-guided radiotherapy. Int J Radiat Oncol Biol Phys 65:378–387

    Article  PubMed  Google Scholar 

  10. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294:1233–1239

    Article  PubMed  CAS  Google Scholar 

  11. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A (2005) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes). Int J Radiat Oncol Biol Phys 63:1463–1468

    Article  PubMed  Google Scholar 

  12. Kagan AR, Schulz RJ (2005) Intensity-modulated radiotherapy for adenocarcinoma of the prostate: a point of view. Int J Radiat Oncol Biol Phys 62:454–459

    Article  PubMed  Google Scholar 

  13. Kupelian P, Willoughby T, Mahadevan A, Djemil T, Weinstein G, Jani S, Enke C, Solberg T, Flores N, Liu D, Beyer D, Levine L (2006) Multi-institutional clinical experience with the calypso system in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys [Epub ahead of print]

  14. Langen KM, Zhang Y, Andrews RD, Hurley ME, Meeks SL, Poole DO, Willoughby TR, Kupelian PA (2005) Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. Int J Radiat Oncol Biol Phys 62:1517–1524

    Article  PubMed  Google Scholar 

  15. Langen KM, Pouliot J, Anezinos C, Aubin M, Gottschalk AR, Hsu IC, Lowther D, Liu YM, Shinohara K, Verhey LJ, Weinberg V, Roach M 3rd (2003) Evaluation of ultrasound-based prostate localization for image-guided radiotherapy. Int J Radiat Oncol Biol Phys 57:635–644

    Article  PubMed  CAS  Google Scholar 

  16. Ghilezan M, Yan D, Liang J, Jaffray D, Wong J, Martinez A (2004) Online image-guided intensity-modulated radiotherapy for prostate cancer: how much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery. Int J Radiat Oncol Biol Phys 60:1602–1610

    Article  PubMed  Google Scholar 

  17. Pinto F, Prayer-Galetti T, Gardiman M, Sacco E, Ciaccia M, Fracalanza S, Betto G, Pagano F (2006) Clinical and pathological characteristics of patients presenting with biochemical progression after radical retropubic prostatectomy for pathologically organ-confined prostate cancer. Urol Int 76:202–208

    Article  PubMed  CAS  Google Scholar 

  18. Salomon L, Anastasiadis AG, Antiphon P, Levrel O, Saint F, De La Taille A, Cicco A, Vordos D, Hoznek A, Chopin D, Abbou CC (2003) Prognostic consequences of the location of positive surgical margins in organ-confined prostate cancer. Urol Int 70:291–296

    Article  PubMed  Google Scholar 

  19. Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, Bergstralh EJ, Zincke H (2000) Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol 163:1189–1190

    Article  Google Scholar 

  20. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Marechal JM, Scalliet P, Haustermans K, Pierart M; European Organization for Research, Treatment of Cancer (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578

    Google Scholar 

  21. Collette L, van Poppel H, Bolla M, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, Pierart M; European Organisation for Research, Treatment of Cancer (EORTC) Radiotherapy and Genito-urinary Groups (2005) Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer 41:2662–2672

    Google Scholar 

  22. Wiegel T, Bottke D, Willich N, Piechota H, Souchon R, Stoeckle M, Ruebe C, Hinke A, Hinkelbein W, Miller K (2005) Phase III results of adjuvant radiotherapy (RT) versus “wait and see” (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). J Clin Oncol 23(Suppl):4513

    Google Scholar 

  23. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296:2329–2335

    Article  PubMed  CAS  Google Scholar 

  24. Bottke D, Wiegel T, Hocht S, Muller M, Schostak M, Hinkelbein W (2003) Salvage radiotherapy in patients with persisting prostate-specific antigen after radical prostatectomy for prostate cancer. Oncology 65(Suppl1):18–23

    Article  PubMed  Google Scholar 

  25. Anscher MS, Robertson CN, Prosnitz LR (1995) Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten year update. Int J Radiat Oncol Biol Phys 33:37–43

    Article  PubMed  CAS  Google Scholar 

  26. Teh BS, Bastasch MD, Mai WY, Kattan MW, Butler EB, Kadmon D (2006) Long term benefits of elective radiotherapy after prostatectomy for patients with positive surgical margins. J Urol 175:2097–2210

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology and Radiotherapy, University Hospital Ulm, Robert-Koch-Straße 6, 89081, Ulm, Germany

    Dirk Bottke & Thomas Wiegel

Authors
  1. Dirk Bottke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Wiegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Wiegel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bottke, D., Wiegel, T. Percutaneous radiotherapy for low-risk prostate cancer: options for 2007. World J Urol 25, 53–57 (2007). https://doi.org/10.1007/s00345-007-0150-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-007-0150-2

Keywords

Search

Navigation